Chemotherapy for Oligodendroglioma: Title and subTitle BreakProgress Report

J. Gregory Cairncross, MD; David R. Macdonald, MD

[+] Author Affiliations

Accepted for publication September 20, 1990.

Reprint requests to London Regional Cancer Centre, 790 Commissioners Rd E, London, Ontario, Canada N6A 4L6 (Dr Cairncross).

Arch Neurol. 1991;48(2):225-227. doi:10.1001/archneur.1991.00530140123026

Text Size: A A A

Published online

Article

References

Comments

ABSTRACT

ABSTRACT | REFERENCES

Six years ago, we began to notice that recurrent oligodendrogliomas, tumors that had regrown after one or more surgeries and radiotherapy, responded to chemotherapy. These tumors were clinically aggressive, contrast-enhancing, histologically anaplastic, and relatively pure. We concluded, after eight consecutive responses (see reference 1 for response criteria),¹ that anaplastic oligodendroglioma was a chemosensitive tumor.² In this article, we review our experience with chemotherapy for this uncommon brain tumor.

Table 1 summarizes the results of treatment for "first" recurrence. We have treated 10 patients, all have responded; two completely and eight partially. Patient 1 responded to carmustine (BCNU), patient 4 to diaziquone (AZQ), the others to a drug combination (PCV) that included procarbazine, lomustine (CCNU), and vincristine.³ (Patient 5 failed to respond to fludarabine, patient 8 to diaziquone; both responded to PCV.) The median duration of response is 15 months (range, 8 to 36 months). All patients have

REFERENCES

ABSTRACT | REFERENCES

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. In press.

Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma . Ann Neurol . 1988;;23:360-364.

Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors . Cancer Treat Rep . 1980;;64:237-241.

Levin VA, Silver P, Hannigan J, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report . Int J Rad Oncol Biol Phys . 1990;;18:321-324.

Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma . Ann Neurol . 1990;;27:573-574.

Cairncross J, Laperriere NJ. Low-grade glioma: to treat or not to treat? Arch Neurol . 1989;;46:1238-1239.

Brown M, Cairncross JG, Vick NA, et al. Differential response of recurrent oligodendrogliomas vs astrocytomas to intravenous melphalan . Neurology . 1990;;40( (suppl 1) ):397.

Saarinen UM, Pihko H, Makipernaa A. High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report . J Neuro-Oncol . 1990;;9:57-62.

Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic glioma in adults: the prognostic importance of extent of resection and prior low grade glioma . J Neurosurg . 1989;;71:487-493.

Macdonald DR, O'Brien RA, Gilbert JJ, Cairncross JG. Metastatic anaplastic oligodendroglioma . Neurology . 1989;;39:1593-1596.

Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S. Distant metastasis in epithelial ovarian cancer . Cancer . 1987;;60:1561-1566.

First Page Preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal